Starbucks Q1 FY26 Earnings Show Sales Gain, Margin Squeeze

Starbucks Q1 FY26 earnings show comps up and a revenue beat while operating margins narrowed and GAAP EPS slightly missed, keeping focus on margins.

January 28, 2026·2 min read
View all news articles
Flat filled vector of a lone coffee cup with dimmed highlights suggesting margin squeeze for Starbucks Q1 FY26 earnings cover

KEY TAKEAWAYS

  • Global comparable-store sales rose 4.0%, driven by 3.0% higher transactions and 1.0% higher average ticket.
  • Revenue beat at $9.9 billion, highlighting top-line strength.
  • Operating income fell to $867 million; operating margin contracted to 11.9%, and GAAP EPS was $0.56.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Starbucks Corp. (SBUX) reported Q1 FY26 earnings on Jan. 28, 2026, with global comparable-store sales rising while operating margins narrowed and GAAP earnings missed consensus. The results highlight a sales-led recovery constrained by profit compression.

Quarterly Results and Outlook

Starbucks said global comparable-store sales increased 4.0% in the 13 weeks ended Dec. 28, 2026, driven by a 3.0% rise in comparable transactions and a 1.0% increase in average ticket. U.S. same-store sales also rose 4.0%, marking the first growth since late 2023. This pattern indicates improving customer visits, though spending per visit grew modestly.

Revenue reached $9.9 billion, exceeding analyst estimates and reflecting strength from higher transactions and seasonal momentum. Despite this top-line gain, GAAP earnings per share fell short, at $0.56 versus the $0.59 consensus.

Operating income declined to $867 million from $1.2 billion a year earlier, with operating margin contracting to 11.9% from 16.7%. The margin compression underscores operational challenges limiting profit recovery despite sales growth.

A prior CEO statement noted a record North American sales day tied to the November 2025 holiday menu launch, illustrating how promotional events supported the region’s momentum during the quarter.

Starbucks issued FY26 EPS guidance alongside the release, setting a benchmark for evaluating whether recent comparable-store gains can translate into sustained profit improvement. Investors will watch for management’s commentary on reconciling rising sales with pressured operating profitability.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.